Press Releases Sirnaomics Ltd.

Equities

2257

KYG2050P1028

Delayed Hong Kong S.E. Other stock markets 04:08:24 2024-07-08 am EDT			5-day change	1st Jan Change
4.05 ^HKD	-0.25%		-5.37%	-88.69%

Jul. 08	Sirnaomics Finds No Serious Adverse Events During Phase 1 Study for Coagulation Drug	MT
Jul. 08	Sirnaomics Anticogulent Agent Successfully Completes 2nd Cohort of Phase I Clinical Study	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sirnaomics Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Therapeutics	Jul. 08	PR
Basal Cell Carcinoma Pipeline 2024 \| PellePharm, MedC Biopharma Corporation, AiViva BioPharma, MediWound, Kintara Therapeutics, IO Biotech, Sirnaomics, Aresus Pharma	Jul. 05	AQ
Sirnaomics Announces Completion of STP707 Phase I Clinical Study with Strong Safety Profile and Disease Activity for the Treatment of Pancreatic Cancer Patients	Jun. 28	PR
Sirnaomics Demonstrates Strong Antitumor Activity of Its Novel Oligonucleotide-ChemoDrug Conjugate in Journal of Oncology Research and Therapy	Jun. 13	PR
Sirnaomics Announces 2023 Annual Results	Mar. 28	PR
Sirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference	Mar. 12	PR
Sirnaomics to Present Latest Developments of STP705 for Focal Fat Reduction at IMCAS World Congress 2024	Feb. 05	PR
Sirnaomics Publishes Novel Mechanism of Action of RNAi Cancer Therapeutic STP707 for Solid Tumors	Jan. 24	PR
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	Dec. 20	AQ
RNAimmune Receives Investigational New Drug Application Clearance from U.S. FDA for mRNA-Based Respiratory Syncytial Virus Vaccine RV-1770	Dec. 18	PR
Sirnaomics Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment	Dec. 05	PR
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer	Dec. 04	AQ
Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer	Dec. 01	PR
Sirnaomics Presents Positive Clinical Data of STP705 for Focal Fat Reduction	Nov. 01	PR
Sirnaomics Announces Successful Phase I Clinical Study of RNAi Therapeutic STP707 for Treatment of Multiple Solid Tumors	23-08-30	PR
Sirnaomics Appoints Dr. Francois Lebel as Senior Vice President for Preclinical and Clinical Development	23-07-27	PR
Sirnaomics to Present Latest Developments on Two Proprietary Delivery Platforms at Upcoming Industry Conferences	23-07-12	PR
Sirnaomics Establishes a Strategic Partnership with EDIRNA Inc., an RNA-Editing Therapeutic Company	23-07-05	PR
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development	23-06-19	PR
Sirnaomics Reports Interim Results of STP705 Phase I Clinical Study for Medical Aesthetics Treatment in Adults Undergoing Abdominoplasty	23-06-05	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Sirnaomics Ltd.

Equities

2257

KYG2050P1028

Press Releases

Filters